Neuraxpharm launches first probiotic product PS128™

New collaboration between Neuraxpharm and Bened Biomedical expands portfolio of Consumer Healthcare products

Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces it will soon launch its first probiotic [1] in the European market following an exclusive licensing agreement with the probiotics company Bened Biomedical Co., Ltd.

Bened Biomedical, an award winning 2015 spin-out from Taiwan-based National Yang-Ming University, develops functional probiotic strains that can alter human microbiome. The agreement secures Neuraxpharm exclusive rights to market its first probiotic, PS128™, in the European market.

This is Neuraxpharm’s first launch of a probiotic product expanding the Company’s portfolio of marketed Consumer Healthcare products. This is in line with its ambition of covering CNS therapeutics from prevention over standard therapeutics to value-added medicines. As the European Consumer Healthcare market continues to grow, this agreement opens new opportunities to promote the benefits of a broader range of probiotics to healthcare professionals and consumers.

Read more 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH